|

BGB-53038 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • BeiGene1

Indications

  • Advanced Gastroesophageal Junction Cancer1
  • Advanced Esophageal Adenocarcinoma1
  • Advanced Non-squamous Non-small-cell Lung Cancer1
  • Advanced Pancreatic Ductal Adenocarcinoma1
  • Advanced Gastric Cancer1

Los Angeles, California1 trial

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Usc Norris Comprehensive Cancer Center (Nccc)

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.